SLC5A2 and diabetes mellitus: The results of this study show that diabetes does not predict a more severe progression of FG. The use of insulin and SGLT-2 inhibitors also failed to predict outcomes. Diabetes is known to be a risk factor for the occurrence of FG, but diabetics respond as well as non-diabetics to treatment. Therefore, it is recommended that diabetic status not be incorporated into the FGSI.